The second quarter of 2025 was a period of dynamic evolution within the biotechnology and pharmaceutical sectors. Critical factors like escalating policy pressures, pipeline pivots by leading companies and the increasingly transformative impact of artificial intelligence (AI) shaped the landscape and presented both challenges and